OneThree Biotech (@onethreebiotech) 's Twitter Profile
OneThree Biotech

@onethreebiotech

Redesigning drug discovery with biology-driven AI.

ID: 775726698541281281

linkhttp://www.onethree.bio calendar_today13-09-2016 16:03:52

75 Tweet

728 Takipçi

175 Takip Edilen

Neel S. Madhukar (@neelmadhukar) 's Twitter Profile Photo

So deserved. Also can we talk about how awesome it is that the prize was 100% given to two amazing female scientists! Is this the first time where a female scientist didn’t share the Chemistry award with male colleagues? nature.com/articles/d4158…

OneThree Biotech (@onethreebiotech) 's Twitter Profile Photo

Our Chief Data Scientist Cory Gilvary is speaking this afternoon about her journey from science to a startup! Info below for anyone interested in checking it out!

OneThree Biotech (@onethreebiotech) 's Twitter Profile Photo

For Breast Cancer Awareness month our Chief Data Scientist Cory Gilvary walked through how OneThree scientists use our gene interaction module to identify targeted, effective treatments! Here's a video showing an example of BRCA1 synthetic lethal partners: youtu.be/_8tkvaMgijI

OneThree Biotech (@onethreebiotech) 's Twitter Profile Photo

Another example of how biology-driven #AI could advance drug development for patients in need – this time in #melanoma, #MDS, & #AML. We're thrilled to partner with Jubilant Therapeutics to pinpoint MoAs & identify new indications for their first in class therapy! prn.to/3nmgbGP

Jubilant Therapeutics (@jubilanttx) 's Twitter Profile Photo

Jubilant Therapeutics is pleased to announce their collaboration with OneThree Biotech and the successful completion of a study focused on identifying specific biomarkers for new indications in targeted oncology patient populations. bit.ly/2IvaqYm #biopharma #drugdevelopment

<a href="/JubilantTx/">Jubilant Therapeutics</a> is pleased to announce their collaboration with <a href="/OneThreeBiotech/">OneThree Biotech</a> and the successful completion of a study focused on identifying specific biomarkers for new indications in targeted oncology patient populations. bit.ly/2IvaqYm  #biopharma #drugdevelopment
CellChorus (@cellchorus) 's Twitter Profile Photo

Join Dan Meyer (CellChorus), Andrew Radin (twoXAR), Brad Pryde (OneThree Biotech) & Ben Paice (Charlton Morris) in a discussion on artificial intelligence in drug discovery on Thursday December 3rd at 8am Pacific / 11am Eastern / 4pm GMT #singlecell crowdcast.io/e/AI-in-drug-/…

Neel S. Madhukar (@neelmadhukar) 's Twitter Profile Photo

Was a pleasure to collaborate with Bhavneet Bhinder Olivier Elemento Cory Gilvary OneThree Biotech on our recent review: "Artificial Intelligence in Cancer Research and Precision Medicine." Touches on multiple applications of AI in discovery & precision med cancerdiscovery.aacrjournals.org/content/11/4/9…

InHerSight (@inhersight) 's Twitter Profile Photo

Meet OneThree Biotech, a biotechnology startup in New York City. Hear from CEO Neel S. Madhukar on what diversity means, how they're incorporating DEI into their company culture, and what their goals are for the next two years. Plus, explore their benefits! inhersight.com/blog/partners-…

Cory Gilvary (@coryandar) 's Twitter Profile Photo

Thrilled to announce this partnership! Having the opportunity to use OneThree Biotech's AI approaches to better understand novel biology is exactly why we built this company. prnewswire.com/news-releases/…

Neel S. Madhukar (@neelmadhukar) 's Twitter Profile Photo

Hello science fam! At OneThree Biotech we hold a monthly journal club with Olivier Elemento and we've been playing around with the idea of hosting them on Clubhouse/twitter spaces to expand community/discussion. 1) what do you guys think? Anyone interested? 2) platform preference?

Neel S. Madhukar (@neelmadhukar) 's Twitter Profile Photo

One of our newest approaches at OneThree Biotech is early prediction of target-derived tox. We predicted that PARP1 inhibition is safer than inhibition of PARP2, & I was excited to see this validated independently by an in-vivo study from AstraZeneca! (bit.ly/3ieZ2io)

One of our newest approaches at <a href="/OneThreeBiotech/">OneThree Biotech</a> is early prediction of target-derived tox.

We predicted that PARP1 inhibition is safer than inhibition of PARP2, &amp; I was excited to see this validated independently by an in-vivo study from <a href="/AstraZeneca/">AstraZeneca</a>!  (bit.ly/3ieZ2io)
Neel S. Madhukar (@neelmadhukar) 's Twitter Profile Photo

Lucy Guo Huge shoutout to my co-founder Cory Gilvary . One of the fastest PhD graduates I know. Worked in a quant hedge fund. And now leads up our AI driven drug discovery efforts at OneThree Biotech

OneThree Biotech (@onethreebiotech) 's Twitter Profile Photo

Very excited to announce a milestone in our partnership with Poolbeg Pharma! OneThree's ATLANTIS Platform enabled Poolbeg to identify novel drug targets and signatures driving RSV infection in under 6 months. This will power the selection of new drug candidates to treat RSV!

OneThree Biotech (@onethreebiotech) 's Twitter Profile Photo

Tune in to learn more about how Poolbeg Pharma is applying OneThree Biotech's ATLANTIS Platform to identify novel drug targets and signatures driving RSV infection! #collaboration #pharma #biotech #ai #onethreebiotech #polb

OneThree Biotech (@onethreebiotech) 's Twitter Profile Photo

OTB joined forces with Poolbeg Pharma plc to discuss the impact that #AI has had in the #pharmaceuticals space! 💊 🔬 Learn about how our platform was used to identify #RSV candidates using AI and our thoughts on current #aitrends 📈 #POLBF #POLB #OTB lnkd.in/ezpruPSs